1000 mg · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Evening primrose oil (EPO) is extracted from the seeds of Oenothera biennis, containing 70–74% linoleic acid (LA) and 8–10% gamma-linolenic acid (GLA) — an omega-6 fatty acid that is converted to dihomo-gamma-linolenic acid (DGLA) and then to prostaglandin E1 (PGE1), a potent anti-inflammatory compound. Standardised to 9% GLA, this product provides a consistent therapeutic dose for skin conditions, hormonal symptoms, and inflammatory disorders.
GLA is a rare omega-6 that bypasses the rate-limiting delta-6-desaturase enzyme, providing a direct precursor to anti-inflammatory PGE1. PGE1 reduces inflammatory cytokines (IL-1β, IL-6, TNF-α), modulates immune responses, and improves skin barrier function by increasing ceramide synthesis. In breast tissue, PGE1 reduces inflammation and pain associated with cyclical mastalgia. For skin, it reduces transepidermal water loss and soothes eczema and atopic dermatitis.
Women with PMS, cyclical mastalgia (breast pain), or menopausal symptoms, individuals with atopic eczema or dermatitis, those with dry or inflamed skin, people with inflammatory conditions, and anyone seeking GLA supplementation. Relevant for Indian women who commonly experience PMS and mastalgia but have limited access to hormonal treatments.
People with epilepsy (EPO may lower seizure threshold in rare cases), those on blood thinners (theoretical anticoagulant effect), individuals with schizophrenia (rare reports of interaction), pregnant or breastfeeding women (limited safety data). Side effects: Very safe. May cause mild stomach upset, nausea, or headache in sensitive individuals. Rarely: increased bleeding risk at very high doses (theoretical). No serious adverse effects at standard doses.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 1969047 (Evening primrose oil and eczema — Lancet, 1990), PMC8105655 (EPO systematic review for eczema, 2021), PMC8296106 (EPO meta-analysis for mastalgia — 13 trials, n=1752, 2021), PMC6718646 (EPO in female ailments review, 2019)
SacredBod's longer take on Evening Primrose High GLA — context the structured blocks above don't capture.
Evening primrose oil has been a staple of natural medicine since the 1980s — a seed oil rich in gamma-linolenic acid (GLA), one of the rare fatty acids that directly produces anti-inflammatory prostaglandin E1. For Indian women dealing with PMS, mastalgia, eczema, or dry skin, standardised EPO offers a well-researched, gentle alternative to hormonal and steroid treatments.
A 1990 Lancet study (PMID 1969047) evaluated evening primrose oil in atopic eczema and found significant improvements in itching, scaling, and overall severity compared to placebo. While later meta-analyses have shown mixed results for eczema specifically, the anti-inflammatory mechanism through PGE1 is well-established.
A 2021 meta-analysis (PMC8296106) pooled 13 RCTs with 1752 women and evaluated EPO for mastalgia (breast pain). The analysis found that EPO was as safe as placebo and other treatments (topical NSAIDs, danazol, vitamin E) with no increased adverse events. While pain reduction was modest compared to danazol, EPO’s safety profile makes it the preferred first-line natural treatment.
A 2019 review (PMC6718646) on EPO in female health cataloged benefits for PMS, mastalgia, hot flashes, and gestational diabetes. The 8–10% GLA content was identified as the active component, with PGE1-mediated anti-inflammatory effects being the primary mechanism.
A 2021 systematic review (PMC8105655) on EPO for eczema concluded that while individual trial results vary, the overall safety profile is excellent and some patients respond very well, particularly those with GLA deficiency or delta-6-desaturase impairment.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
